Journal
GENES
Volume 14, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/genes14040886
Keywords
deubiquitinating enzyme; epithelial ovarian cancer; ubiquitin-proteasome system
Categories
Ask authors/readers for more resources
In ovarian cancer, the survival rate is much higher for early stages than for advanced stages. However, most patients are diagnosed in the advanced stages and often experience recurrence. To address this, new biomarkers for early diagnosis and treatment are needed. This review focuses on deubiquitinating enzymes and their regulated substrates in ovarian cancer cells, which could aid in the discovery of biomarkers and therapeutic candidates.
In ovarian cancer patients, the 5-year survival rate is 90% for stages I and II, but only 30% for stages III and IV. Unfortunately, as 75% of the patients are diagnosed at stages III and IV, many experience a recurrence. To ameliorate this, it is necessary to develop new biomarkers for early diagnosis and treatment. The ubiquitin-proteasome system is a post-translational modification that plays an important role in regulating protein stability through ubiquitination. In particular, deubiquitinating enzymes (DUBs) regulate protein stability through deubiquitinating substrate proteins. In this review, DUBs and substrates regulated by these enzymes are summarized based on their functions in ovarian cancer cells. This would be useful for the discovery of biomarkers for ovarian cancer and developing new therapeutic candidates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available